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In sporadic clear cell renal cell carcinoma (CCRCC), the von Hippel Lindau (VHL) gene is
inactivatedbymutationormethylationinthemajorityofprimary(P)tumors.Duetodiffering
effects of wild-type (WT) and mutant (MT) VHL gene on downstream signaling pathways
regulating angiogenesis,VHL gene status could impact clinical outcome. In CCRCC, com-
parative genomic hybridization analysis studies have reported genetic differences between
pairedPandmetastatic(M)tumors.WethussequencedtheVHLgeneinpairedtumorspec-
imensfrom10patientstodetermineapossibleclonalrelationshipbetweenthePtumorand
M lesion(s) in patients with CCRCC. Using parafﬁn-embedded specimens, genomic DNA
from microdissected samples (>80% tumor) of paired P tumor and M lesions from all 10
patients,aswellasinnormaltissuefrom6ofthesecases,wasanalyzed.TheDNAwasused
for PCR-based ampliﬁcation of each of the 3 exons of the VHL gene. Sequences derived
from ampliﬁed samples were compared to the wild-type VHL gene sequence (GenBank
Accession No. AF010238). Methylation status of theVHL gene was determined usingVHL
methylation-speciﬁc PCR primers after DNA bisulﬁte modiﬁcation. In 4/10 (40%) patients
the VHL gene status differed between the P tumor and the M lesion. As expected, when
theVHL gene was mutated in both the P tumor and M lesion, the mutation was identical.
Further, while theVHL genotype differed between the primary tumor in different kidneys or
multiple metastatic lesions in the same patient, theVHL germline genotype in the normal
adjacent tissue was always wild-type irrespective of the VHL gene status in the P tumor.
These results demonstrate for the ﬁrst time that the VHL gene status can be different
between paired primary and metastatic tissue in patients with CCRCC.
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INTRODUCTION
The major types of epithelial renal tumors include clear cell
(75%), papillary (15%), chromophobe (5%), and oncocytoma
(5%). Mutations in the von Hippel Lindau (VHL) tumor sup-
pressor gene are associated with hereditary and sporadic forms
of clear cell renal carcinoma only. The product of the VHL gene
forms a heterodimeric complex with elongin C, elongin B, Cul-2,
and RBX1 and targets the hypoxic inducible factors (HIF1α and
HIF1β)forubiquitin-mediateddegradation.Mutationof theVHL
gene in clear cell kidney cancer prevents the VHL complex from
targeting HIFs for degradation, resulting in their accumulation.
Increased levels of HIF result in increased transcription of down-
streamtargetsincludingVEGFandangiogenicpathways(Linehan
et al.,2010).
Over the last few years, anti-VEGF therapies have made
a major impact in the standard of care for patients with
advanced clear cell renal cell carcinoma (CCRCC; Patard
et al., 2011). These include bevacizumab (Yang et al., 2003),
sunitinib (Motzer et al., 2006), axitinib (Rixe et al., 2007),
pazopanib (Sternberg et al., 2010), and sorafenib (Motzer et al.,
2007).
We had previously reported the possible impact of VHL
gene mutation and promoter hypermethylation on the out-
come toVEGF-targeted agents in patients with advanced CCRCC
(Choueiri et al., 2008). While the overall response rate (ORR)
to VEGF-targeted therapy in patients with metastatic RCC was
not correlated with VHL inactivation, subset analysis suggested
that loss of function VHL mutations may identify patients with
increased ORR toVEGF-targeted agents.
Extensive genetic differences between matched primary and
metastatic tumors in 6 out of 19 CCRCC cases following compar-
ative genomic hybridization (CGH) analysis (Bissig et al., 1999)
and intra-tumoral heterogeneity of VHL gene deletions (Moch
etal.,1998)havebeenreported.Basedontheavailabilityof paired
primary and metastatic tumors from 10 patients, the goal of this
exploratory study was to determine whether the VHL genotype
can indeed differ in these paired tissue samples.
MATERIALS AND METHODS
DNA SEQUENCE ANALYSIS
Genomic DNA was isolated from formalin ﬁxed parafﬁn-
embedded (FFPE) tumor biopsies as described in Choueiri et al.
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(2008) after manual micro dissection (Blaveri et al., 2005). Sam-
ples that were at least 80% tumor, as determined by a patholo-
gist (HA and MZ), were included in the study. A total of seven
primer sets were used to amplify overlapping fragments of the
coding region of the VHL gene (Figure 1). Due to inherent
problems with quality of DNA extracted from FFPE specimens,
three primer sets, two primer sets, and two primer sets were
used to amplify exons 1, 2, and 3, respectively. The PCR reac-
tions consisted of 100ng of genomic DNA, 67mM Tris-HCL, pH
8.8, 6.7mM magnesium chloride, 16.6mM ammonium sulfate,
10mM 2-mercaptoethanol, 12.5mM dNTP’s, and 10% DMSO,
0.5μM primers, and 0.25 units of Platinum Taq polymerase
(Invitrogen, Carlsbad, CA, USA). The primer sequences used
were as follows: Exon 1A–F: 5 -CGAAGACTACGGAGGTCGAC-
3 ;1A–R:5 -TCTTCAGGGCCGTACTCTTCG-3 ;1B–F:5 -AGGC
CGAGGTAGGCGCGGA-3 ; 1B–R: 5 -GCAGAAGATGACCTGG
GAGGGC-3 ; 1C–F: 5 -CTGCGCTCGGTGAACTCG-3 ; 1C–R:
5 -CTATCGTCCCTGCTGGGTCG-3 ;2 A – F  :5  -GGATTACAG
GTGTGGGCCAC-3 ;2 A – R  :5  -GGCTGTCCGTCAACATTGAG-
3 ; 2B–F: 5 -ACGATGGGCTTCTGGTTAAC-3 ; 2B–R: 5 -
CCTGTACTTACCACAACAACC-3 ; 3A–F: 5 -TCCTTGTACTGA
GACCCTAG-3 ; 3A–R: 5 -TTTGGGTGGTCTTCCAGATC-3 ;
3B–F: 5 -ATTACAGGAGACTGGACATC-3 ; 3B–R: 5 -CCAGTCC
TGTATCTAGATC-3 .
TheampliconsunderwentSangersequencingusingtheABI377
automated sequencer (Applied Biosystems, Foster City, CA, USA)
at the Genomic’s Core Facility, Lerner Research Institute, Cleve-
land Clinic. Sequences derived from the ampliﬁed samples were
compared to the wild-type VHL sequence (GenBank Accession
No.AF010238)usingLaserGenesoftware(DNAStar,PerkinElmer,
Foster City, CA, USA) to identify mutations. A subset of samples
was also sent to Transgenomics (Omaha, NE, USA) for inde-
pendent analysis of the VHL genotype. Sequence variations were
identiﬁed on PCR-ampliﬁed samples that were screened using the
mismatchcleavageenzyme,Surveyor,andDHPLC/WAVE®analy-
ses followed by sequencing at Transgenomic (Nickerson et al.,
2008).
METHYLATION ASSAY
Methylation status was determined using VHL methylation-
speciﬁc PCR primers after DNA bisulﬁte modiﬁcation. Genomic
DNA was modiﬁed using the EZ DNA Methylation-Gold Kit
accordingtothemanufacturer’sprotocol(ZymoResearch,Orange,
CA,USA). The product then underwent PCR-based ampliﬁcation
usingmethylation-speciﬁcprimersdescribedpreviously(Herman
et al., 1996). Methylation status was determined by gel elec-
trophoresis of the PCR products as described in Herman et al.
(1996).
RESULTS AND DISCUSSION
Paired primary and metastatic tumors were obtained from 10
patients.VHLgenotypeanalysisinthis10patientcohortincluded
single biopsies from a single primary and metastatic lesion (5
patients),multiple primary and/or metastatic tumors (5 patients)
and adjacent normal tissue (6 patients). Sequencing data was
obtained from a total of 42 samples (18 primary tumors, 14
metastatic tumors, and 10 adjacent normal tissues). Due to the
intrinsic difﬁculty in identifying true somatic mutations in tissues
with genetic heterogeneity, a subset of 16 samples comprised of 8
primary and 8 metastatic samples were also analyzed by Transge-
nomic for independent assessment of VHL gene mutation status
(Table 1). VHL genotype assessment of adjacent normal tissue,
as well as evaluation of multiple samples where possible con-
tributed to the validation of our data. Patient cohort included six
men and four women. While the primary and metastatic tumors
were obtained in most patients during a single surgery, in some
patientssubsequentsurgeryinvolvedadditionalmetastaticlesions
or primary tumor in the contra lateral kidney (Table 1, patients
6 and 10).
A total of seven patients harbored mutations in the VHL
gene in the primary and/or metastatic lesions, 1 patient exhibited
VHL gene methylation, and two patients had the wild-type VHL
genotype (Table 1; Figure 1). Sequencing traces identifying VHL
genotype for data in Table 1 are included as FigureA1 in Appen-
dix. Mutations identiﬁed in this study were not observed in our
FIGURE1|S c hematic ofVHL gene mutations identiﬁed in the patient cohort. *Patient ID number. **Overlapping regions ampliﬁed by PCR.
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T a b l e1|v o nHippel Lindau genotype and Fuhrman grade in primary and metastatic CCRCC tumors.
Pat. ID Sample ID Surgery date Primary (P)/metastatic
(M)/normal
VHL genotype Fuhrman grade
Gr. 1/2 Gr. 3/4
CATEGORY 1: PATIENTSWITH IDENTICAL PRIMARYAND METASTATICVHL GENOTYPE INTUMORS
4 1 12/2004 Primary, left kidney (P) WT Not evaluated
4 2 12/2004 Metastatic, lymph node (M) WT Not evaluated
5 3 8/2002 Primary, left kidney (P) 478delG, ex3 0 100
5 4 8/2002 Metastatic, lymph node (M) 478delG,ex3 0 100
5 5 8/2002 Adjacent normal WT
8 6 2/2005 Primary, right kidney (P) Methylated
Promoter
20 80
8 7 2/2005 Metastatic, adrenal (M) Methylated
Promoter
01 0 0
9* 8 8/2003 Primary, left kidney (P) 232delA,ex1 10 90
Renal tumor
9 9 8/2003 Primary, left kidney (P) 232delA,ex1 89 11
Tumor close to capsule
9* 10 8/2003 Metastatic, lymph node (M) 232delA, ex1 95 5
11 11 2/2004 Primary, left kidney (P) 349delT,ex1 10 90
11 12 2/2004 Metastatic, small bowel (M) 349delT,ex1 50 50
11 13 2/2004 Adjacent normal WT
13 14 3/2004 Primary, right kidney (P) WT 100 0
13 15 3/2004 Metastatic, left adrenal (M) WT 99 1
13 16 3/2004 Adjacent normal WT
CATEGORY 2: PATIENTSWITH DIFFERENT PRIMARYAND METASTATICVHL GENOTYPE INTUMORS
6* 17 5/2003 Primary, left kidney (P) 407insATATATAT, ex2 100 0
6* 18 5/2004 Metastatic, fallopian tube (M) WT 100 0
6* 19 5/2004 Metastatic, fallopian tube (M) WT 100 0
6* 20 5/2004 Metastatic fallopian tube (M) 407insATATATAT, ex2 100 0
6 21 5/2003 Adjacent normal WT
7* 22 8/2004 Primary, left kidney (P) WT 100 0
7* 23 8/2004 Metastatic, colon (M) G463C, ex2 0 100
10* 24 9/2002 Primary, right kidney (P) WT 90 10
Renal vein margin with tumor
10* 25 9/2002 Primary, right kidney (P) C333G, ex1 10 90
Spatially separated representative section of
primary tumor
10* 26 12/2003 Primary, left kidney (P) C333G, ex1 45 55
Representative section of tumor in relation to
capsular margin
10* 27 12/2003 Primary, left kidney (P) C333G, ex1 66 34
Representative section of tumor in relation to
parenchymal margin
10* 28 12/2003 Metastatic, lymph node (M) C333G, ex1 100 0
10 29 9/2002 Adjacent normal WT
10 30 12/2003 Adjacent normal WT
10 31 12/2003 Adjacent normal WT
12 32 3/2004 Primary, right kidney (P) del31 bp, intron 1,
9nt before ex2
95 5
Representative section of closest
parenchymal margin including area with renal
sinus bulge of tumor
(Continued)
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Table 1 | Continued
Pat. ID Sample ID Surgery date Primary (P)/metastatic
(M)/normal
VHL genotype Fuhrman grade
Gr. 1/2 Gr. 3/4
12 33 3/2004 Primary, right kidney (P) del31 bp in intron 1,
9nt before ex2
95 5
Representative section of closest
parenchymal margin including area with renal
sinus bulge of tumor
12 34 3/2004 Primary, right kidney (P) del31 bp in intron 1,
9nt before ex2
95 5
Representative section of same primary
12* 35 4/2004 Primary, left kidney (P) WT 90 10
Sections of tumor with capsule
12 36 4/2004 Primary, left kidney (P) WT 50 50
Same primary
12* 37 3/2004 Lung metastasis WT 10 90
Parenchymal line of resection
12* 38 3/2004 Lung metastatsis WT 10 90
Pleural margin of tumor
12 39 3/2004 Lung metastasis WT 10 90
Remaining metastatic tissue
12 40 3/2004 Adjacent normal WT
12 41 3/2004 Adjacent normal WT
12 42 3/2004 Adjacent normal WT
All nucleotide positions are numbered with the adenosine of the AUG start site as position number 1. This corresponds to nt position 214 in the mRNA sequence
GenBank accession no. NM_000551. DNA sequencing traces are included in Appendix.
*Samples that were also sent toTransgenomic.
previous larger 123 patient cohort of primary tumors (Choueiri
et al., 2008) suggesting that mutations were unique to the patient
in which it was ﬁrst described. Further, no two patients had iden-
tical VHL mutations and methylation in this and our previous
study (Choueiri et al., 2008) was observed only where the VHL
genotype was wild-type. The VHL gene was methylated in 12 out
123 patients (10%) in the Choueiri study (Choueiri et al., 2008).
Notablyin4outof 10patientstheVHL genotypedifferedbetween
the primary and matched metastatic lesion. Also in 2 of these
patients, while the primary tumor was wild-type a mutant VHL
genotype was identiﬁed in the paired metastatic lesion (patient #7
and #10, Table 1) likely due to intra-tumor heterogeneity. Inter-
and intra-tumor heterogeneity in VHL genotype is exempliﬁed
in patients 10 and 12 (Table 1) between the primary tumor in
different kidneys as well as metastasis removed at surgery. Addi-
tional data supporting heterogeneity inVHL genotype is based on
identiﬁcationof wild-typeandmutantVHL intheprimarytumor
(patient#10and#12)andinmetastasis(patient#6)whendifferent
microdissectedtumorareaswereanalyzed.VHL mutations,when
present, were identical between primary and metastatic sites and
the VHL genotype in adjacent normal tissue in all 6/10 patients
analyzed was wild-type, irrespective of VHL gene status of tumor
tissue.VHLmutationstatuswasnotfoundtocorrelatewithtumor
grade (Table 1).
Polyclonality in colorectal adenomas (Thirwell et al., 2010),
genetic heterogeneity in tumors with mutations in a single gene
(Dalgliesh et al., 2010) and genetic diversity based on single cell
sequencing (Navin et al., 2011) suggests that the focus on spe-
ciﬁc genetic lesions for personalized targeted therapy may be
overly simplistic. More recently (while this manuscript was under
review), intra-tumor heterogeneity in RNA expression or inacti-
vating mutations in renal carcinoma has been reported (Gerlinger
et al., 2012). The present study and previous reports (Moch et al.,
1998; Bissig et al., 1999) emphasize that multiple genetically dif-
ferent clones are possibly present in clear cell renal carcinoma and
thiscouldcontributetotheobserveddifferencesinVHL genotype
between the primary and metastatic tumor in the same patient.
Since the patients in this study had sporadic CCRCC, it is likely
that clonal heterogeneity and mutations in the VHL gene may
occur either during tumor development or subsequent tumor
progression. This possibility is supported by the heterogeneity
in VHL genotype within a single primary (Patient 6) or metas-
tasis (Patient 12) when different spatially separated tumor sites
was analyzed for VHL genotype. It is also becoming increasingly
apparent that several targets for current cancer therapies can also
display discordance in expression or mutation status between pri-
mary and metastatic sites. Previous studies in breast (Torres et al.,
2007) and melanoma (Katona et al., 2007) cases have reported
extensive genetic heterogeneity between primary and metasta-
tic tumors. Detailed assessments of PIK3CA mutations between
primary and matched metastatic breast tumors report not only
discordance in mutations but also microheterogeneity in muta-
tional status of the primary tumor (Dupont Jensen et al., 2011).
Similarly, discordance in HER2 expression between primary and
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paired metastatic breast cancer tumors is reported to occur at a
signiﬁcant rate (Fabi et al., 2011; Houssami et al., 2011). Even
in a CCRCC study of unmatched primary tumors and metasta-
tic lesions,signiﬁcant differences between primary and metastatic
renal tumors in the expression levels of several proteins involved
in the mTOR pathway including phos-AKT, phos-S6, 4EBP1, and
c-mycwerereported(Schultzetal.,2011).Insummary,thesestud-
ies suggest marked molecular heterogeneity between primary and
metastatic solid tumors.
TheVHL geneisuniqueinthatsomaticmutationsareobserved
only with kidney tumors and the aberrant signaling due to
VHL mutations has a direct effect on the angiogenic path-
way. Although VHL is classiﬁed as a tumor suppressor, nearly
20% of sporadic CCRCC harbor the wild-type VHL genotype.
While the observed differences in VHL genotype between the
primary and metastatic tumor could be ascribed to technical
issues, results from the present study were independently vali-
dated in 13/16 samples by Transgenomic (Table A1 in Appendix)
using previously reported methodology (Nickerson et al., 2008)
and further, the adjacent normal tissue in all cases indepen-
dent of the tumor VHL genotype was wild-type VHL since the
patients had sporadic CCRCC. In summary, in CCRCC, since
primary tumor nephrectomy can precede a subsequent primary
in the contralateral kidney and/or metastatic disease, the present
results on intra- and inter-tumor heterogeneity in wild-type or
mutant VHL gene suggest that reliance on VHL genotype of the
primary tumor for treatment strategy may not be completely
informative.
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APPENDIX
TableA1 | Comparison ofVHL genotype calls – Cleveland Clinic andTransgenomic (n =16 samples).
Patient ID Sample ID DNA sequenced at Cleveland Clinic DNA sequenced and reported byTransgenomic
6Pa 407insATATATAT, ex2 412inATATATAT, ex2
6Mb 18 wt wt
6M 19 wtc 412insATATATAT, ex2
6M 20 407insATATATAT, ex2 412insATATATAT, ex2
7P wtd G463C
7M G463C G463C
9P 232delA 232 delA
9M 232delAe P25S, 10% RSIf
10P 24 wt wt
10P 25 C333G C333G
10P 26 C333G C333G
10P 27 C333G C333G
10M C333G C333G
12P wt wt
12M 37 wt wt
12M 38 wt wt
aPrimary.
bMetastatic.
c,d,eCalls based on sequence traces presented in FigureA1.
fRelative signal intensity (RSI).
www.frontiersin.org May 2012 | Volume 2 | Article 51 | 7Vaziri et al. VHL heterogeneity in renal tumors
Pa ent 5
Primary
478delG
Met
478delG
Normal
wt
FIGUREA1 | Continued
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Pa ent  6
Met
wt
Primary
407insATATATAT
Met
wt
FIGUREA1 | Continued
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Pa ent 6
Met
407insATATATAT
Normal
wt
FIGUREA1 | Continued
Pa ent 7 Primary
wt G463
Met
G463C
FIGUREA1 | Continued
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Pa ent 9
Reverse complementary
sequence for all tracings 
reported for pa ent 9
Primary
mut232delA
Primary
mut232delA
Met
mut232delA
FIGUREA1 | Continued
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Pa ent 10
Primary
wt
Primary
mutC333G
Primary
mutC333G
FIGUREA1 | Continued
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Pa ent 10 Primary
mutC333G
Met
C333G
Normal
wt
FIGUREA1 | Continued
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Pa ent 10
Normal
wt
Normal
wt
FIGUREA1 | Continued
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Pa ent 11 Primary
349delT
Met
349delT
Normal
wt
FIGUREA1 | Continued
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Pa ent 12
Reverse complementary
sequence for all tracings
reported for pa ent 12
Primary
del31nt
9nt before exon2
Primary
del31nt
9nt before exon2
Primary
del31nt
9nt before exon2
FIGUREA1 | Continued
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Pa ent 12 Primary
wt
Primary
wt
Met
wt
FIGUREA1 | Continued
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Pa ent   12 Met
wt
Met
wt
Normal
wt
FIGUREA1 | Continued
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Pa ent 12 Normal
wt
Normal 
wt
FIGUREA1 | SomaticVHL mutation sequencing in normal and tumor tissue of representative patients fromTable 1.
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